Showing results 1 to 20 of 21
next >
| Issue Date | Title | Author(s) |
| 2018 | Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern | Cortes, Jorge E.; Jiang, Qian; Wang, Jianxiang; Weng, Jianyu; Zhu, Huanling; Liu Xiaoli; Hochhaus, Andreas; Kim, Dong-Wook; Radich, Jerald; Savona, Michael R.; Regueira, Patricia Martin; Sy, Oumar; Gurnani, Renuka; Saglio, Giuseppe |
| Apr-2020 | Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study | Cortes, Jorge E.; Jiang, Qian; Wang, Jianxiang; Weng, Jianyu; Zhu, Huanling; Liu, Xiaoli; Hochhaus, Andreas; Kim, Dong-Wook; Radich, Jerald; Savona, Michael; Martin-Regueira, Patricia; Sy, Oumar; Gurnani, Renuka; Saglio, Giuseppe |
| 2-Nov-2023 | Efficacy, Safety, and Survival Findings after Long-Term Follow-up from ZGJAK002, a Phase 2 Study Comparing Jaktinib 100 Mg Twice Daily with 200 Mg Once Daily for Myelofibrosis (MF) | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Suo, Shanshan; Yu, Wenjuan; Jin, Jie |
| 2024 | Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yin, Hewen; Suo, Shanshan; Yu, Wenjuan; Jin, Jie |
| 1-Jan-2021 | Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study | Zhang, Li; Meng, Li; Liu, Bingcheng; Zhang, Yanli; Zhu, Huanling; Cui, Jiuwei; Sun, Aining; Hu, Yu; Jin, Jie; Jiang, Hao; Zhang, Xi; Li, Yan; Liu, Li; Zhang, Wanggang; Liu, Xiaoli; Gu, Jian; Qiao, Jianhui; Ouyang, Guifang; Liu, Xin; Luo, Jianmin; Jiang, Ming; Xie, Xiaobao; Li, Jianyong; Zhao, Chunting; Zhang, Mei; Yang, Tonghua; Wang, Jianxiang |
| 2019 | Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study. | Li, Zhang; Meng, Li; Zhang, Yanli; Zhu, Huanling; Cui, Jiuwei; Sun, Aining; Hu, Yu; Jin, Jie; Jiang, Hao; Zhang, Xi; Li, Yan; Liu, Qifa; Liu, Li; Zhang, Wanggang; Gu, Jian; Qiao, Jian-Hui; Liu, Bingcheng; Zhang, Fengkui; Guo, Yong; Wang, Jianxiang |
| 15-Nov-2022 | Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study | Yang, Sen; Zhang, Xiaoshuai; Zhang, Yanli; Du, Xin; Weng, Jianyu; Zhu, Huanling; Pan, Ling; Yang, Yun-fan; Meng, Li; Liu, Zhenfang; Liu, Xiaoli; Xu, Na; Chen, Chunyan; Wang, Xiaodong; Liang, Rong; Huang, Jian; Li, Guohui; Liu, Chunshui; Lin, Hai; Hu, Jianda; Fei, Li; Liu, Bingcheng; Li, Weiming; Liu, Zhuogang; Yang, Wei; Huang, Xiao Jun; Jiang, Qian |
| 8-Jun-2021 | Mental Health in Persons With Chronic Myeloid Leukemia During the SARS-CoV-2 Pandemic: The Need for Increased Access to Health Care Services | Bao, Mei; Yang, Sen; Gale, Robert Peter; Zhang, Yanli; Liu, Xiaoli; Zhu, Huanling; Liang, Rong; Liu, Bingcheng; Zhou, Li; Li, Zongru; Dou, Xuelin; Shi, Dayu; Wang, Tao; Meng, Li; Li, Weiming; Jiang, Qian |
| 2012 | Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Micafungin versus Itraconazole for Prophylaxis of Invasive Fungal Infections in Patients undergoing Hematopoietic Stem Cell Transplant | Huang, Xiaojun; Chen, Huan; Han, Mingzhe; Zou, Ping; Wu, Depei; Lai, Yongrong; Huang, He; Chen, Xiequn; Liu, Ting; Zhu, Huanling; Wang, Jianmin; Hui, Jianda |
| 18-Aug-2022 | Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial | Jiang, Qian; Li, Zongru; Qin, Yazhen; Li, Weiming; Xu, Na; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Liang, Yang; Hu, Yu; Liu, Xiaoli; Song, Yongping; Men, Lichuang; Chen, Zi; Niu, Qian; Wang, Hengbang; Lu, Ming; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| 31-Oct-2022 | Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022) | Jiang, Qian; Li, Zongru; Qin, Yazhen; Li, Weiming; Xu, Na; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Liang, Yang; Hu, Yu; Liu, Xiaoli; Song, Yongping; Men, Lichuang; Chen, Zi; Niu, Qian; Wang, Hengbang; Lu, Ming; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| 20-Feb-2023 | Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022) | Jiang, Qian; Li, Zongru; Qin, Yazhen; Li, Weiming; Xu, Na; Liu, Bingcheng; Zhang, Yanli; Meng, Li; Zhu, Huanling; Du, Xin; Chen, Suning; Liang, Yang; Hu, Yu; Liu, Xiaoli; Song, Yongping; Men, Lichuang; Chen, Zi; Niu, Qian; Wang, Hengbang; Lu, Ming; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| 15-Nov-2022 | A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy | Zhang, Xiaoshuai; Liu, Bingcheng; Huang, Jian; Zhang, Gongli; Liu, Xiaoli; Xu, Na; Li, Weiming; Du, Xin; Weng, Jianyu; Lin, Hai; Liang, Rong; Chen, Chunyan; Zhu, Huanling; Pan, Ling; Yang, Yun-fan; Wang, Xiaodong; Li, Guohui; Liu, Zhuogang; Liu, Zhenfang; Hu, Jianda; Liu, Chunshui; Fei, Li; Yang, Wei; Meng, Li; Gale, Robert Peter; Huang, Xiao Jun; Jiang, Qian |
| 2-Nov-2023 | A Predictive Scoring System for Therapy Failure of Tyrosine-Kinase Inhibitors in Patients with Chronic-Phase Chronic Myeloid Leukemia | Zhang, Xiao-shuai; Liu, Bingcheng; Huang, Jian; Du, Xin; Zhang, Yanli; Xu, Na; Liu, Xiaoli; Li Weiming; Lin, Hai; Zhu, Huanling; Yang, Yunfan; Pan, Ling; Huang, Xiao-jun; Jiang, Qian |
| 2019 | The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview | Baccarani, Michele; Castagnetti, Fausto; Gugliotta, Gabriele; Rosti, Gianantonio; Soverini, Simona; Albeer, Ali; Pfirrmann, Markus; Bekadja, Mohamed-Amine; Entasoltan, Badra; Nachi, Mourad; Elghandour, Ashraf; El Sorady, Manal; Abdelfattah, Raafat; El Nahass, Yasser; Samra, Mohamed; Azzazi, Mohammed; Elsobki, Ezat; Moussa, Mohamed; Fahmy, Omar; Mattar, Mervat; Shehata, Samir Eid; Azmy, Emad; Bolarinwa, Rahman A.; Eid, Samir; Khelif, Abderrhaim; Hached, Farhat; Menif, Samia; Rahman, Hafizur; Huang, Xiaojun; Jiang, Qian; Ye, Yuanxin; Zhu, Huanling; Chen, Suning; Varma, Neelam; Ganesan, Prasanth; Gundeti, Sadashivudu; Malhotra, Hemant; Radhakrishnan, Vivek S.; Kumar, Lalit; Sharawat, Surender Kumar; Seth, Tulika; Ausekar, B. V.; Balasubramanian, Poonkuzhali; Poopak, Behzad; Inokuchi, Koiti; Kim, Dong-Wook; Al Kindi, Salam; Mirasol, Angelina; Qari, Mohammed; Goh, Yeow Tee; Shih, Lee-Yung; Branford, Susan; Lion, Thomas; Valent, Peter; Burgstaller, Sonja; Thaler, Joseph; Labar, Boris; Zadro, Renata; Mayer, Jiri; Zackova, Daniela; Faber, Edgar; Pallisgaard, Niels; Xavier-Mahon, Francois; Lippert, Eric; Cayuela, Jean Michel; Rea, Delphine; Millot, Frederic; Suttorp, Meinolf; Hochhaus, Andreas; Niederwieser, Dietger; Saussele, Susanne; Haferlach, Torsten; Jeromine, Sabine; Panayiotidis, Panayiotis; Conneally, Eibhlin; Langabeer, Steve; Nagler, Arnon; Rupoli, Serena; Santoro, Nicola; Albano, Francesco; Castagnetti, Fausto; Ottaviani, Emanuela; Rambaldi, Alessandro; Stagno, Fabio; Molica, Stefano; Biagiotti, Caterina; Scappini, Barbara; Lemoli, Roberto; Iurlo, Alessandra; Pungolino, Ester; Menna, Giuseppe; Pane, Fabrizio; Gottardi, Enrico; Rege-Cambrin, Giovanna; Binotto, Gianni; Putti, Maria Caterina; Falzetti, Franca; Visani, Giuseppe; Galimberti, Sara; Musto, Pellegrino; Abruzzese, Elisabetta; Breccia, Massimo; Giona, Fiorina; Chiusolo, Patrizia; Sica, Simona; Fava, Carmen; Ferrero, Dario; Tiribelli, Mario; Bonifacio, Massimiliano; Griskevicius, Laimonas; Musteata, Vasile; Janssen, Jeroen; Prejzner, Witold; Sacha, Tomasz; Waclaw, Joanna; Almeida, Antonio Medina; Kulikov, Sergei; Turkina, Anna; Bogdanovic, Andrija; Zupan, Irena; Marce, Silvia; Cervantes, Francisco; Steegmann, Juan Luis; Kotlyarchuk, Konstyantyn; Milner, Benedict J.; Rose, Susan; Clench, Tim; Waits, Paula; Austin, Steve; Wickham, Caroline; Clark, Richard; Apperley, Jane; Claudiani, Simone; Foroni, Letizia; Szydlo, Richard; Burt, Emma; Bescoby, Ruth; Cork, Leanne; O'Brien, Stephen; Green, Bethaney; Hawtree, Sarah; Watson, Mark; Bengio, Raquel Maria; Larripa, Irene; Pavlovsky, Carolina; Moiraghi, Beatriz; Requiao de Pinna, Cristiane Almeida; Romani Magalhaes, Gustavo Henrique; Pagnano, Katia; Funke, Vaneuza; Tavares, Renato Sampaio; Prado, Adriana; Azevedo, Alita Andrade; Fogliatto, Laura; Bonecker, Simone; Centrone, Renato; Moellman, Artur; Conchon, Monika; Centurion, Maria Elida; Prado, Ana-Ines; Lopez, J. L.; Petruzziello, Fara; Bendit, Israel |
| Oct-2022 | Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial | Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yu, Wenjuan; Jin, Jie |
| 15-Nov-2022 | Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor | Zhang, Xiaoshuai; Liu, Bingcheng; Huang, Jian; Zhang, Gongli; Liu, Xiaoli; Xu, Na; Li, Weiming; Du, Xin; Weng, Jianyu; Lin, Hai; Liang, Rong; Chen, Chunyan; Zhu, Huanling; Pan, Ling; Yang, Yun-fan; Wang, Xiaodong; Li, Guohui; Liu, Zhuogang; Liu, Zhenfang; Hu, Jianda; Liu, Chunshui; Fei, Li; Yang, Wei; Meng, Li; Gale, Robert Peter; Huang, Xiao Jun; Jiang, Qian |
| 2015 | Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase | Xu, Lanping; Zhu, Huanling; Hu, Jianda; Wu, Depei; Jiang, Hao; Jiang, Qian; Huang, Xiaojun |
| 23-Nov-2021 | Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 (T315I)-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) | Qian, Jiang; Shi, Dayu; Li, Zongru; Hou, Yue; Hu, Yu; Li, Weiming; Liu, Xiaoli; Xu, Na; Song, Yongping; Zhang, Gongli; Meng, Li; Hong, Zhenya; Liu, Bingcheng; Li, Yan; Chen, Suning; Xue, Mengxing; Zhu, Huanling; Li, He; Du, Xin; Lou, Jin; Zhang, Xiaohan; Liang, Yang; Dai, Yujun; Chen, Zi; Niu, Qian; Men, Lichuang; Yang, Dajun; Zhai, Yifan; Huang, Xiaojun |
| 15-Nov-2022 | Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation | Jiang, Qian; Li, Zongru; Hou, Yue; Hu, Yu; Li, Weiming; Liu, Xiaoli; Xu, Na; Zhang, Yanli; Song, Yongping; Meng, Li; Hong, Zhenya; Liu, Bingcheng; Li, Yan; Chen, Suning; Xue, Mengxing; Zhu, Huanling; Li, He; Du, Xin; Lou, Jin; Zhang, Xiaohan; Liang, Yang; Dai, Yu-Jun; Chen, Zi; Niu, Qian; Men, Lichuang; Yang, Dajun; Zhai, Yifan; Huang, Xiao-Jun |
